| Jigar Kanubhai Shah, MD | |
|
274 Clear Sky Ct, Clarksville Cancer Care, Clarksville, TN 37043-5653 | |
| (931) 802-8056 | |
| (931) 802-8059 |
| Full Name | Jigar Kanubhai Shah |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 25 Years |
| Location | 274 Clear Sky Ct, Clarksville, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013936079 | NPI | - | NPPES |
| 33358601 | Medicaid | TN | |
| 4119802 | Other | TN | BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MD39642 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tennova Healthcare-clarksville | Clarksville, TN | Hospital |
| Entity Name | Cancer Care, Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265628226 PECOS PAC ID: 9830285873 Enrollment ID: O20071022000500 |
News Archive
Scientists from the Department of Nuclear Medicine and Tracer Kinetics at Osaka University developed a novel system for targeted cancer radiation therapy that uses gold nanoparticles labeled with astatine-211.
St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company's portfolio of solutions for cardiovascular healthcare professionals at the 21st annual Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The featured products reflect the company's continued commitment to developing comprehensive, high-performance solutions which advance the practice of interventional cardiology by improving efficiencies and giving physicians more control.
In the last of a series of posts on the U.K. Department for International Development's (DfID) blog examining the department's work in Malawi, Neil Squires, DfID head of profession for health, looks at the sustainability of the country's HIV/AIDS program.
Children with autism, people with spine and brain injuries and the long-term disabled in job programs are among the 30,000 people who would lose state help under a $5.1 billion spending plan approved by a House committee Thursday.
Newly identified germline variations in a key tumor suppressor gene predispose individuals to develop leukemia as children and leave them with a 1-in-4 chance of developing a second cancer later. St. Jude Children's Research Hospital scientists led the study, which appears today in the Journal of Clinical Oncology.
› Verified 1 days ago
| Entity Name | Healthstar Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801675426 PECOS PAC ID: 6800246810 Enrollment ID: O20240103000065 |
News Archive
Scientists from the Department of Nuclear Medicine and Tracer Kinetics at Osaka University developed a novel system for targeted cancer radiation therapy that uses gold nanoparticles labeled with astatine-211.
St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company's portfolio of solutions for cardiovascular healthcare professionals at the 21st annual Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The featured products reflect the company's continued commitment to developing comprehensive, high-performance solutions which advance the practice of interventional cardiology by improving efficiencies and giving physicians more control.
In the last of a series of posts on the U.K. Department for International Development's (DfID) blog examining the department's work in Malawi, Neil Squires, DfID head of profession for health, looks at the sustainability of the country's HIV/AIDS program.
Children with autism, people with spine and brain injuries and the long-term disabled in job programs are among the 30,000 people who would lose state help under a $5.1 billion spending plan approved by a House committee Thursday.
Newly identified germline variations in a key tumor suppressor gene predispose individuals to develop leukemia as children and leave them with a 1-in-4 chance of developing a second cancer later. St. Jude Children's Research Hospital scientists led the study, which appears today in the Journal of Clinical Oncology.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jigar Kanubhai Shah, MD 404 Savannah Trace Dr, Clarksville, TN 37043-5442 Ph: (931) 802-8056 | Jigar Kanubhai Shah, MD 274 Clear Sky Ct, Clarksville Cancer Care, Clarksville, TN 37043-5653 Ph: (931) 802-8056 |
News Archive
Scientists from the Department of Nuclear Medicine and Tracer Kinetics at Osaka University developed a novel system for targeted cancer radiation therapy that uses gold nanoparticles labeled with astatine-211.
St. Jude Medical, Inc. (NYSE:STJ) today announced it will display products and technologies from the company's portfolio of solutions for cardiovascular healthcare professionals at the 21st annual Transcatheter Cardiovascular Therapeutics meeting in San Francisco. The featured products reflect the company's continued commitment to developing comprehensive, high-performance solutions which advance the practice of interventional cardiology by improving efficiencies and giving physicians more control.
In the last of a series of posts on the U.K. Department for International Development's (DfID) blog examining the department's work in Malawi, Neil Squires, DfID head of profession for health, looks at the sustainability of the country's HIV/AIDS program.
Children with autism, people with spine and brain injuries and the long-term disabled in job programs are among the 30,000 people who would lose state help under a $5.1 billion spending plan approved by a House committee Thursday.
Newly identified germline variations in a key tumor suppressor gene predispose individuals to develop leukemia as children and leave them with a 1-in-4 chance of developing a second cancer later. St. Jude Children's Research Hospital scientists led the study, which appears today in the Journal of Clinical Oncology.
› Verified 1 days ago
Oba Hashim Hollie, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 511 8th St, Clarksville, TN 37040 Phone: 931-245-3580 Fax: 931-201-5868 | |
Dr. Fausta Ditah, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 647 Dunlop Ln Ste 210, Clarksville, TN 37040 Phone: 931-502-3810 Fax: 931-502-3815 | |
Nathan Lidsky, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1481 Hollis Rdg, Clarksville, TN 37043 Phone: 847-987-2121 | |
James R Smith, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 344 Peartree Dr, Clarksville, TN 37043 Phone: 931-648-1811 | |
Dr. Sriram Krishnasamy, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 298 Clear Sky Ct, Suite B, Clarksville, TN 37043 Phone: 931-542-2647 Fax: 931-542-2648 | |
Vernon M Carrigan, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 490 Dunlop Ln, Clarksville, TN 37040 Phone: 931-245-8300 Fax: 931-245-8360 |